Cardiac Troponin T: Smaller Molecules in Patients with End-Stage Renal Disease than after Onset of Acute Myocardial Infarction

We have found previously that in acute myocardial infarction (AMI), cardiac troponin T (cTnT) is degraded in a time-dependent pattern. We investigated whether cTnT forms differed in patients with chronic cTnT increases, as seen with renal dysfunction, from those in the acute phase of myocardial infa...

Full description

Saved in:
Bibliographic Details
Published in:Clinical chemistry (Baltimore, Md.) Md.), 2017-03, Vol.63 (3), p.683-690
Main Authors: Mingels, Alma M A, Cardinaels, Eline P M, Broers, Natascha J H, van Sleeuwen, Anneke, Streng, Alexander S, van Dieijen-Visser, Marja P, Kooman, Jeroen P, Bekers, Otto
Format: Article
Language:English
Subjects:
Acute Disease
Antibodies
Calcium-binding protein
Chromatography
Diagnostic systems
End-stage renal disease
Fragments
Gel filtration
Heart attacks
Heart diseases
Hemodialysis
Humans
Immunoassay
Immunoglobulins
Immunoprecipitation
Investigations
Kidney diseases
Kidney Failure, Chronic - blood
Kidney Failure, Chronic - therapy
Kidney transplantation
Mortality
Myocardial infarction
Myocardial Infarction - blood
Myocardial Infarction - therapy
Patients
Quality control
Renal Dialysis
Renal function
Troponin
Troponin T
Troponin T - blood
Troponin T - chemistry
Western blotting
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We have found previously that in acute myocardial infarction (AMI), cardiac troponin T (cTnT) is degraded in a time-dependent pattern. We investigated whether cTnT forms differed in patients with chronic cTnT increases, as seen with renal dysfunction, from those in the acute phase of myocardial infarction. We separated cTnT forms by gel filtration chromatography (GFC) in end-stage renal disease (ESRD) patients: prehemodialysis (pre-HD) and post-HD (n = 10) and 2 months follow-up (n = 6). Purified (cTnT) standards, quality control materials of the clinical cTnT immunoassay (Roche), and AMI patients' sera also were analyzed. Immunoprecipitation and Western blotting were performed with the original cTnT antibodies from the clinical assay and antibodies against the N- and C-terminal end of cTnT. GFC analysis revealed the retention of purified cTnT at 27.5 mL, identical to that for cTnT in quality controls. For all ESRD patients, one cTnT peak was found at 45 mL, pre- and post-HD, and stable over time. Western blotting illustrated that this peak corresponded to cTnT fragments
ISSN:0009-9147
1530-8561
DOI:10.1373/clinchem.2016.261644